GENEART receives European Patent for Screening Process for Antiviral Therapeutics
System for screening of antiviral therapeutics is based on customized synthetic genes
GENEART AG, informs of being awarded patent EP 1 356 111 "Kernexportreportersystem" ("Nucleus Export Reporter System") by the European patent office. The patent describes a new screening system based on synthesized virus-like reporter genes with which a new class of antiviral drug candidates may be identified.
Thus allowing to analyze by high-throughput processes to which extent such drug candidates block the export of viral messenger RNA from the cell nucleus and therefore suppress virus propagation. Additionally, this process may be used for identification of DNA motives positively affecting production rates of cell factories and therefore production costs of proteins.
The patent covers Austria, Switzerland, Spain, Liechtenstein, France, the United Kingdom, Luxemburg, the Netherlands, Sweden, Belgium, Italy and Germany. The German patent of this family of patents had been granted as early as 2008. An application for a comparable protection for North America has been filed under the international patent process.
"With being granted the European patent, we did not only protect a process with which new antiviral active agents can be identified based on optimized genes, now we also have another proprietary technology available, beside our gene optimizing software GeneOptimizer®, to systematically improve production efficiency of protein-based therapeutics and vaccines. This emphasizes again our exceptional position as development partner for the pharmaceutical industry as well as the innovative potential of synthetic genes for research", explained Prof. Dr. Ralf Wagner, CEO of GENEART AG.
Most read news
Topics
Organizations
Other news from the department research and development
These products might interest you
![Limsophy](https://img.chemie.de/Portal/Products/171141_oET-PI88c.png?tr=n-xl10)
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
![LAUDA.LIVE](https://img.chemie.de/Portal/Products/63ea0985866d3_GEwUzh7Q_.jpg?tr=n-xl10)
LAUDA.LIVE by LAUDA
LAUDA.LIVE - The digital platform for your device management
Comprehensive fleet management options for every LAUDA device - with and without IoT connectivity
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.